Hypothesis

We propose that the senescence-associated secretory phenotype (SASP) from aged Leydig cells directly suppresses StAR and TSPO expression through NF‑κB‑dependent recruitment of histone deacetylases (HDACs) and DNA methyltransferases to their promoters, creating an epigenetic block that persists despite intact LH signaling and mitochondrial cholesterol import capacity.

Mechanistic Rationale

1. SASP factor identification – Single‑cell transcriptomics shows subsets of senescent Leydig cells overexpressing IL‑1β, IL‑6, and CCL2 3. These cytokines activate NF‑κB signaling in neighboring Leydig cells.
2. Epigenetic coupling – NF‑κB p65 can bind HDAC1/2 and DNMT3A complexes, leading to deacetylation of histone H3 lysine 27 (H3K27ac) and increased CpG methylation at steroidogenic gene promoters 4. In aged rats, Star and Tspo promoters display reduced H3K27ac and elevated 5‑mC, correlating with their 52‑74% and 30‑50% declines 1, 2.
3. Mitochondrial independence – Even when cholesterol reaches mitochondria via TSPO rescue or M1‑mediated fusion, P450scc activity remains low if Star transcription is silenced, explaining why mitochondrial interventions only partially restore testosterone 4.

Testable Predictions

• Prediction 1: Pharmacological inhibition of NF‑κB (e.g., with BAY 11‑7082) in aged rat testes will increase H3K27ac at Star and Tspo promoters, raise StAR/TSPO mRNA, and elevate serum testosterone without altering mitochondrial mass.
• Prediction 2: Senolytic clearance of p16^INK4a^‑positive Leydig cells (using navitoclax) will reduce IL‑1β levels, decrease HDAC/DNMT recruitment to Star/Tspo promoters, and restore steroidogenesis to youthful levels.
• Prediction 3: Overexpression of an acetylation‑mimic Star promoter (e.g., CRISPR‑dCas9‑p300 targeted to Star enhancer) in senescent Leydig cells will rescue testosterone production even when TSPO remains low.

Falsifiability

If NF‑κB inhibition or senolytic treatment fails to alter promoter acetylation/methylation or does not improve StAR/TSPO expression and testosterone despite verified reduction in SASP factors, the hypothesis is refuted. Likewise, if epigenetic editing of Star restores transcription but testosterone does not rise, the causal link between StAR/TSPO and functional output would be questioned.

Translational Implication

This framework bridges cellular senescence biology and molecular endocrinology, suggesting that combined senolytic and epigenetic therapies (e.g., HDAC inhibitors) could more effectively reverse late‑onset hypogonadism than mitochondrial‑targeted approaches alone.

References

• StAR/TSPO decline in aging Leydig cells 1
• LH responsiveness despite steroidogenic block 2
• Single‑cell SASP landscape 3
• NF‑κB‑HDAC/DNMT coupling in gene repression 4
• Senolytic trials in endocrine disorders 5
• Stem‑cell derived Leydig cell challenges 6